BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21359153)

  • 1. Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.
    Holt GE; Podack ER; Raez LE
    Therapy; 2011 Jan; 8(1):43-54. PubMed ID: 21359153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome.
    Shepherd FA; Douillard JY; Blumenschein GR
    J Thorac Oncol; 2011 Oct; 6(10):1763-73. PubMed ID: 21876456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in lung cancer.
    Villaruz LC; Kalyan A; Zarour H; Socinski MA
    Transl Lung Cancer Res; 2014 Feb; 3(1):2-14. PubMed ID: 25806276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for lung cancer: ongoing clinical trials.
    Declerck S; Vansteenkiste J
    Future Oncol; 2014 Jan; 10(1):91-105. PubMed ID: 24143916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
    Perez CA; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
    Reck M
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for non-small-cell lung cancer.
    Thomas A; Jakopovic M
    Expert Opin Biol Ther; 2014 Aug; 14(8):1061-4. PubMed ID: 24878420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic vaccines in non-small cell lung cancer.
    Socola F; Scherfenberg N; Raez LE
    Immunotargets Ther; 2013; 2():115-24. PubMed ID: 27471692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why has active immunotherapy not worked in lung cancer?
    Thomas A; Giaccone G
    Ann Oncol; 2015 Nov; 26(11):2213-20. PubMed ID: 26232492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
    Hall RD; Gray JE; Chiappori AA
    Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer.
    Daly ME; Monjazeb AM; Kelly K
    J Thorac Oncol; 2015 Dec; 10(12):1685-93. PubMed ID: 26484629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
    Rodríguez PC; Rodríguez G; González G; Lage A
    MEDICC Rev; 2010; 12(1):17-23. PubMed ID: 20387330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune modulation as a therapeutic strategy for non-small-cell lung cancer.
    Holt GE; Disis ML
    Clin Lung Cancer; 2008 Feb; 9 Suppl 1():S13-9. PubMed ID: 18540530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.